JP2003534370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003534370A5 JP2003534370A5 JP2001587745A JP2001587745A JP2003534370A5 JP 2003534370 A5 JP2003534370 A5 JP 2003534370A5 JP 2001587745 A JP2001587745 A JP 2001587745A JP 2001587745 A JP2001587745 A JP 2001587745A JP 2003534370 A5 JP2003534370 A5 JP 2003534370A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- formulation according
- formulation
- lipid component
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 16
- 238000009472 formulation Methods 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001499 Heparinoid Polymers 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 125000005481 linolenic acid group Chemical group 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10026699A DE10026699A1 (de) | 2000-05-30 | 2000-05-30 | Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage |
| DE10026699.1 | 2000-05-30 | ||
| PCT/EP2001/006115 WO2001091729A1 (de) | 2000-05-30 | 2001-05-29 | Formulierung auf heparin-, glycosaminoglykan- oder heparinoidbasis und verwendung der formulierung sowie der formulierungsgrundlage |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003534370A JP2003534370A (ja) | 2003-11-18 |
| JP2003534370A5 true JP2003534370A5 (https=) | 2008-07-10 |
| JP5198708B2 JP5198708B2 (ja) | 2013-05-15 |
Family
ID=7644040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001587745A Expired - Fee Related JP5198708B2 (ja) | 2000-05-30 | 2001-05-29 | ヘパリン、グリコサミノグリカン、またはヘパリン類似物質に基づく製剤と製剤および製剤ベースの使用。 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7393840B2 (https=) |
| EP (1) | EP1284717B1 (https=) |
| JP (1) | JP5198708B2 (https=) |
| CN (1) | CN100391440C (https=) |
| AT (1) | ATE349202T1 (https=) |
| AU (1) | AU2001266033A1 (https=) |
| BR (1) | BR0111257A (https=) |
| CA (1) | CA2409828C (https=) |
| DE (2) | DE10026699A1 (https=) |
| ES (1) | ES2278750T3 (https=) |
| NO (2) | NO20025759L (https=) |
| RU (1) | RU2278658C2 (https=) |
| WO (1) | WO2001091729A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
| CA2359945C (en) * | 1999-11-12 | 2011-04-26 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
| DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| AU2002221935A1 (en) * | 2000-12-16 | 2002-06-24 | Aventis Pharma Deutschland Gmbh | Use of low molecular heparin for treating osteoarthritis |
| GB0205868D0 (en) * | 2002-03-13 | 2002-04-24 | Univ Nottingham | Polymer composite with internally distributed deposition matter |
| CA2484604C (en) * | 2002-05-03 | 2011-08-02 | Massachusetts Institute Of Technology | .delta. 4,5 glycuronidase and uses thereof |
| SE0201922D0 (sv) * | 2002-06-20 | 2002-06-20 | Ltp Lipid Technologies Provide | Koagulationshindrande komposition (Anticoagulant Composition) |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| AU2004285747A1 (en) * | 2003-10-23 | 2005-05-12 | University Of Nottingham | Preparing active polymer extrudates |
| US7988962B2 (en) * | 2003-12-02 | 2011-08-02 | Universiteit Gent | Use of polysulphated alginate in cellular matrices |
| EP1537871A1 (en) * | 2003-12-04 | 2005-06-08 | Aventis Pharma S.A. | Enoxaparin for the treatment of cancer |
| US7563780B1 (en) * | 2004-06-18 | 2009-07-21 | Advanced Cardiovascular Systems, Inc. | Heparin prodrugs and drug delivery stents formed therefrom |
| JP5258144B2 (ja) * | 2004-12-21 | 2013-08-07 | 株式会社分子生理化学研究所 | 吸収性の改善された固形状のコエンザイムｑ１０経口製剤の製造方法 |
| US7691830B2 (en) * | 2005-02-17 | 2010-04-06 | Clive Elson | Method and composition for treatment of a mucosal tissue disorder |
| MY148074A (en) * | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
| US8802156B2 (en) * | 2007-11-14 | 2014-08-12 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
| GB0812742D0 (en) * | 2008-07-11 | 2008-08-20 | Critical Pharmaceuticals Ltd | Process |
| WO2010068891A2 (en) * | 2008-12-11 | 2010-06-17 | L'oreal S.A. | Lengthening mascara composition |
| WO2010113176A2 (en) * | 2009-03-31 | 2010-10-07 | Reliance Life Sciences Pvt. Ltd. | Novel copolymers for controlled release delivery system |
| ES2363964B1 (es) | 2009-11-20 | 2012-08-22 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados. |
| US8871741B2 (en) * | 2010-01-15 | 2014-10-28 | Icahn School Of Medicine At Mount Sinai | Inhibition of TNF-α induced activation of NFKB by pentosan polysulfate |
| US10897918B1 (en) * | 2013-03-15 | 2021-01-26 | Mccormick & Company, Incorporated | Extrusion encapsulation with narrow particle size and shape distribution, high solubility, and low surface oil |
| WO2014142938A1 (en) * | 2013-03-15 | 2014-09-18 | Aihol Corporation | Pharmaceutical formulation containing glycosaminoglycan |
| US9539265B2 (en) | 2013-03-15 | 2017-01-10 | Aihol Corporation | Pharmaceutical formulation containing glycosaminoglycan |
| JP6877996B2 (ja) * | 2016-12-27 | 2021-05-26 | 小林製薬株式会社 | 外用組成物 |
| JP6877997B2 (ja) * | 2016-12-27 | 2021-05-26 | 小林製薬株式会社 | 外用組成物 |
| WO2019236453A1 (en) * | 2018-06-03 | 2019-12-12 | Glycomira Therapeutics, Inc. | Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and /or chemotherapy |
| US20210069237A1 (en) * | 2019-09-09 | 2021-03-11 | Harrow Ip, Llc | Pharmaceutical compositions comprising heparinoids and methods for preparing thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1107041A (en) * | 1913-10-25 | 1914-08-11 | Benjamin H Cook | Coupling device. |
| JPS58101311A (ja) * | 1981-12-11 | 1983-06-16 | Toshiba Corp | 多相電圧電流変換回路 |
| DE3331009A1 (de) * | 1983-08-27 | 1985-03-14 | Basf Ag, 6700 Ludwigshafen | Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat |
| JPS6054313A (ja) * | 1983-09-01 | 1985-03-28 | Terumo Corp | 腸管吸収性ヘパリン組成物 |
| EP0545913B1 (en) * | 1986-08-18 | 1999-02-24 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents |
| SE9200951D0 (sv) * | 1992-03-27 | 1992-03-27 | Kabi Pharmacia Ab | Pharmaceutical composition containing a defined lipid system |
| US5346701A (en) * | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
| SE9302135D0 (sv) * | 1993-06-18 | 1993-06-18 | Kabi Pharmacia Ab | New pharmaceutical composition |
| AU692506B2 (en) * | 1993-11-17 | 1998-06-11 | Ibah, Inc. | Transparent liquid for encapsulated drug delivery |
| US6333021B1 (en) * | 1994-11-22 | 2001-12-25 | Bracco Research S.A. | Microcapsules, method of making and their use |
| DE19531277A1 (de) * | 1995-08-25 | 1997-02-27 | Basf Ag | Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren |
| FR2775188B1 (fr) | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
| DE69917609T2 (de) * | 1998-03-05 | 2005-06-09 | Phares Pharmaceutical Research N.V., Curaçao | Arzneimittel und deren verwendung |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
-
2000
- 2000-05-30 DE DE10026699A patent/DE10026699A1/de not_active Withdrawn
-
2001
- 2001-05-29 RU RU2002135623/15A patent/RU2278658C2/ru not_active IP Right Cessation
- 2001-05-29 JP JP2001587745A patent/JP5198708B2/ja not_active Expired - Fee Related
- 2001-05-29 WO PCT/EP2001/006115 patent/WO2001091729A1/de not_active Ceased
- 2001-05-29 CN CNB018133312A patent/CN100391440C/zh not_active Expired - Fee Related
- 2001-05-29 AU AU2001266033A patent/AU2001266033A1/en not_active Abandoned
- 2001-05-29 US US10/296,441 patent/US7393840B2/en not_active Expired - Fee Related
- 2001-05-29 ES ES01943457T patent/ES2278750T3/es not_active Expired - Lifetime
- 2001-05-29 AT AT01943457T patent/ATE349202T1/de not_active IP Right Cessation
- 2001-05-29 CA CA2409828A patent/CA2409828C/en not_active Expired - Fee Related
- 2001-05-29 EP EP01943457A patent/EP1284717B1/de not_active Expired - Lifetime
- 2001-05-29 BR BR0111257-0A patent/BR0111257A/pt not_active Application Discontinuation
- 2001-05-29 DE DE50111738T patent/DE50111738D1/de not_active Expired - Lifetime
-
2002
- 2002-11-29 NO NO20025759A patent/NO20025759L/no not_active Application Discontinuation
- 2002-11-29 NO NO20025755A patent/NO20025755D0/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003534370A5 (https=) | ||
| CA2409828A1 (en) | Formulation based in heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base | |
| RU2002135623A (ru) | Рецептура на основе гепарина, глюкозаминогликана или гепариноида и применение рецептуры и ее основы | |
| EP2462923A3 (en) | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions | |
| US7560120B2 (en) | Vehicles for delivery of biologically active substances | |
| CA2403831A1 (en) | Coating and binding agent for pharmaceutical formulations having improved storage stability | |
| RU2013156437A (ru) | Композиция и способы улучшения стабильности и продления срока хранения чувствительных пищевых добавок и пищевых продуктов из них | |
| CA2408915A1 (en) | Self-emulsifying active substance formulation and use of this formulation | |
| KR890001521A (ko) | 서방형 신규 제약 제제물 | |
| JP4209467B2 (ja) | 経口投与用製剤組成物 | |
| JPH02235817A (ja) | 新規シクロスポリン製剤 | |
| TW200608975A (en) | Pharmaceutical compositions | |
| JP2002536315A5 (https=) | ||
| WO2006048895B1 (en) | Aqueous pharmaceutical coating | |
| BRPI0614417A2 (pt) | composições farmacêuticas compreendendo bloqueadores de canais de cálcio de dihidropiridina e ácidos graxos de Èmega-3 e métodos de tratamento utilizando as mesmas | |
| RU2005122439A (ru) | Композиция, включающая фенофибриновую кислоту, ее физиологически приемлемую соль или производное | |
| JP2021169510A5 (https=) | ||
| CA2445388A1 (en) | Stabilized medicine-releasing compositions | |
| JP5193674B2 (ja) | 貼付剤および貼付製剤 | |
| KR20140006083A (ko) | 안정화된 프로스타글란딘 ｅ 화합물의 국소 투여 제형 | |
| MXPA04006256A (es) | Formulaciones transdermicas adhesivas de diclofenac sodico. | |
| JP2006509038A5 (https=) | ||
| EE05231B1 (et) | Tramadoolvesinikkloriidi sisaldav toimeainet reguleeritult vabastav ravimkoostis ja meetod selle valmistamiseks | |
| JP4377123B2 (ja) | 皮膚外用剤組成物 | |
| JP6609803B2 (ja) | 義歯安定剤 |